Apogee Therapeutics, Inc. filings document a clinical-stage biotechnology issuer focused on antibody programs for inflammatory and immunology indications. The company’s Form 8-K disclosures cover operating results, Regulation FD clinical-data presentations for zumilokibart (APG777), APG279 and APG333 development activity, and material agreements related to public common-stock offerings.
Proxy materials cover annual meeting matters, director elections, board composition, executive compensation, equity awards and shareholder voting. The filings also identify APGE common stock on The Nasdaq Global Market and provide recurring capital-structure, governance, clinical or regulatory, and financial disclosures tied to the company’s research and development model.
Apogee Therapeutics reported a larger quarterly net loss as it continues to invest heavily in its inflammatory and immunology pipeline. For the three months ended March 31, 2026, net loss was $74.1M compared with $55.3M a year earlier, driven by higher research and development and general and administrative expenses.
R&D spending rose to $60.8M from $46.4M, while G&A increased to $22.0M from $16.7M. The company ended the quarter with substantial liquidity, including $451.8M in cash and cash equivalents, $608.1M in marketable securities and $198.4M in long‑term marketable securities, and believes this will fund operations for at least 12 months. Apogee also highlights positive Phase 2 data for its lead antibody zumilokibart in atopic dermatitis, supporting its strategy to develop differentiated biologics across major inflammatory indications.
Apogee Therapeutics reported a larger net loss but strong cash position for the first quarter of 2026 while highlighting significant pipeline progress. Net loss was $74.1 million for the quarter ended March 31, 2026, compared with $55.3 million a year earlier, driven by higher R&D and G&A spending.
R&D expenses rose to $60.8 million from $46.4 million, and G&A expenses increased to $22.0 million from $16.7 million, reflecting expansion of zumilokibart and combination programs and higher personnel costs. Cash, cash equivalents, marketable securities and long‑term marketable securities totaled $1.3 billion as of March 31, 2026, up from $902.9 million on December 31, 2025, supported by an upsized public equity offering with approximately $403 million in gross proceeds.
The company reported strong 52‑week Phase 2 APEX Part A data for zumilokibart in atopic dermatitis, with high maintenance of EASI‑75 and IGA 0/1 responses on 3‑ and 6‑month dosing, and plans to start Phase 3 trials in the second half of 2026. Interim positive Phase 1b asthma results, advancing combination assets APG279 and APG273, and a stated cash runway into 2029 underpin plans to pursue a future BLA filing for zumilokibart in atopic dermatitis.
Apogee Therapeutics Chief Medical Officer Carl Dambkowski reported a mix of stock sales and option exercises. On May 6, 2026, he completed open-market sales totaling 5,500 shares of common stock at weighted average prices of $84.60 and $83.92 per share under a pre-arranged Rule 10b5-1 trading plan.
He also exercised 4,125 stock options at an exercise price of $22.86 per share, converting options into common stock. A related option grant covers 175,345 shares that vest in forty-eight equal monthly installments through December 18, 2027, conditioned on his continued service.
APGE reported an intended sale of 22,000 common shares under Rule 144, comprised of 16,500 shares from exercised stock options and 5,500 shares from restricted stock awards.
The filing also discloses two 10b5-1 sales in the past three months totaling 11,000 shares (5,500 on 2026-04-01 for $466,639.80 and 5,500 on 2026-03-04 for $390,839.05).
Apogee Therapeutics, Inc. Chief Financial Officer Jane Henderson executed pre-planned open-market sales of company common stock. On May 1, 2026, she sold a total of 2,000 shares in three transactions at reported weighted average prices between about $81 and $83 per share, under a Rule 10b5-1 trading plan adopted on September 2, 2025. Following these sales, she directly holds 173,371 shares of Apogee common stock.
Insider sales reported under Rule 144 via 10b5-1 plan. The filing lists five separate 10b5-1 dispositions by Jane Henderson of 2,000 shares each on 02/02/2026, 03/02/2026, 03/25/2026, 04/01/2026, and 04/16/2026, with proceeds shown for each trade.
Apogee Therapeutics, Inc. will hold its 2026 virtual annual meeting on June 9, 2026 at 11:00 a.m. Eastern Time to vote on three proposals. Stockholders of record as of April 15, 2026, when 61,853,254 shares of voting common stock were outstanding, may participate.
Investors will elect three Class III directors to terms ending at the 2029 meeting, ratify Ernst & Young LLP as independent auditor for 2026, and cast a non-binding advisory vote on named executive officer pay. The board recommends voting “FOR” all proposals.
The proxy details Apogee’s classified board, supermajority voting for key charter and bylaw changes, and limits on stockholder special meetings and written consents. It highlights a pay-for-performance program in which 2025 bonuses paid at 130% of target, with CEO base salary at $700,000 and other named executives at $540,000.
Apogee Therapeutics, Inc. reported that two directors, Andrew Gottesdiener, M.D. and Peter Harwin, have notified the Board of their intention to resign effective May 11, 2026. The company states these resignations are not due to any disagreement regarding its operations, policies or practices.
Following their departure, the size of the Board will be reduced from nine directors to seven directors, consolidating governance among a smaller group of board members.
Apogee Therapeutics, Inc. Chief Executive Officer Michael Thomas Henderson exercised stock options to acquire 3,000 shares of common stock at $22.86 per share. Following this exercise, he directly holds 1,135,987 shares of common stock.
The exercised options are part of a grant representing the right to purchase 398,512 shares, which vests in forty-eight equal monthly installments over four years, subject to his continued service. After this transaction, 387,012 options from this grant remain outstanding and are scheduled to expire on December 18, 2033.